stock decline

Class action lawsuit filed against Varonis Systems for allegedly making false statements about SaaS conversion abilities. Stock plunged 48.67% after missing revenue guidance.

Paysafe faces securities fraud lawsuit after missing revenue targets by $5.8M and reporting $87.7M loss. Stock fell 27.6%. Shareholders have April deadline to file.

Palo Alto Networks stock fell 10-11% after beating Q2 earnings but issuing cautious Q3 guidance below consensus, triggering analyst downgrades.

JIADE Limited launches $3M direct equity offering of 12M shares at $0.25 each. Stock fell 8.13% on announcement; potential $12M if all options exercised.

Trilogy Metals shares tumbled after reporting a $42.2 million full-year loss and major investor Paulson & Co. exiting its position entirely.

Yeti stock fell 12% despite beating earnings and raising 2026 guidance, driven by profit-taking after a 40% rally and CFO transition uncertainty.

BellRing Brands faces securities lawsuit for allegedly misrepresenting organic growth, claiming revenue gains were actually from customer inventory stockpiling rather than genuine demand.

Molson Coors beat EPS expectations but missed revenue forecasts, declining 2.7% year-over-year. Stock fell 7% on weak guidance and revenue concerns.

REGENXBIO faces class action lawsuit over allegedly false safety disclosures for gene therapy RGX-111. FDA clinical hold triggered 17.8% stock drop after adverse trial findings.

DoorDash missed Q4 earnings and revenue expectations, reporting $0.48 EPS versus $0.60 consensus. Stock fell 7% in after-hours trading.

Class action lawsuits filed against Ultragenyx and Mereo after Phase III clinical trials for setrusumab failed. Stock prices plummeted 42% and 88% respectively following the announcement.

Gemini Space Station stock tumbled 12.9% after three senior executives departed and an analyst downgraded the company, citing concerns about operational stability and strategic direction.

uniQure stock plummeted 49% after FDA rejected accelerated approval for gene therapy AMT-130, triggering a class action lawsuit alleging securities fraud.

BellRing Brands faces securities fraud lawsuit for allegedly failing to disclose significant inventory issues. Stock fell 52% during the class period amid operational challenges.

Valaris shares fell 7% as the company delayed earnings due to pending $5.8 billion merger with Transocean. Investor caution reflects uncertainty over merger timing and offshore drilling sector weakness.

Law firm Pomerantz LLP investigates First Western Financial for potential securities violations following earnings miss and 8.81% stock drop on January 23, 2026.

Pomerantz investigates First Citizens BancShares for potential securities fraud following disappointing Q4 earnings and weak guidance, triggering an 8.49% stock decline.

Devon Energy beat earnings and revenue expectations with improved operational efficiency, but shares fell 1.7% in after-hours trading, reflecting broader market concerns beyond quarterly results.

REGENXBIO faces securities lawsuit over alleged false statements about gene therapy safety. Investors have until April 14 deadline to join class action after FDA clinical hold.

Law firm Block & Leviton investigates GEMI for potential securities violations after three senior executives departed amid 10% stock decline and 25% workforce reduction.